A second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report by Carolina Mensi et al.
CASE REPORT Open Access
A second case of pericardial mesothelioma
mimicking systemic lupus erythematosus in
the literature in over 30 years: a case report
Carolina Mensi1, Alessandro Romano2*, Alvise Berti3, Roberto Dore4 and Luciano Riboldi1
Abstract
Background: Mesothelioma is a rare neoplasm which commonly develops in the pleura of people exposed to asbestos.
Pericardial mesothelioma accounts for only 0.7 % of all malignant mesotheliomas and it usually presents with pericardial
effusion, mimicking serositis. To date, there are approximately 200 cases of pericardial mesothelioma described in the
medical literature, and little knowledge exists about the systemic manifestations of this pathology. The first and only
described case of pericardial mesothelioma with autoimmune features dates back to 1984 and, in our case report, we
describe the second.
Case presentation: We report a case of a 45-year-old white woman whose pericardial mesothelioma was initially
misdiagnosed as pericardial involvement of an autoimmune disease (systemic lupus erythematosus). After several relapses
of pericardial effusion, a computed tomography scan and a biopsy with histological analysis were performed revealing
neoplastic growth.
Conclusions: We describe a rare case of pericardial mesothelioma in a patient with a clinical presentation compatible
with lupus serositis. Clinicians should consider malignant mesothelioma in the differential diagnosis of pericardial effusion,
especially when it is recurrent and not clearly explained by other causes. Cytological samples should always be obtained
and, if imaging tools are suggestive for solid processes, histological confirmation is mandatory.
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Background
Pericardial mesothelioma (PM) is a very rare neoplastic en-
tity which accounts for only 0.7 % of all malignant meso-
theliomas (MMs) [1]. It is characterized by a very high
mortality rate, since it develops in the pericardium and can
manifest with relapsing pericardial effusion and heart tam-
ponade thus leading to acute hearth failure. Besides, diag-
nosis is often made at later stages [2, 3]. Asbestos is
considered to be among the principal risk factors of devel-
oping MM, especially when serous membranes are involved
[1]. There are three main histopathological pictures of ma-
lignant PM: the epithelial, the biphasic, and the sarcoma-
toid histotypes. Epithelial and biphasic histotypes are more
common than the third histotype, accounting together for
approximately 75 to 80 % of the total of MM cases [3]. As
regards treatment options, surgery is recommended at
earliest stages while radiotherapy and chemotherapy can be
considered in later stage for palliative purposes [4]. To date,
approximately 200 cases of PM have been described in the
medical literature, and little knowledge exists about the sys-
temic manifestations of this pathology. The first and only
described case of PM with autoimmune features dates back
to 1984 [5] and, in our case report, we describe the second.
The relevance of this report is to inform clinicians about
the rare presentation of this neoplastic condition with
symptoms and signs – that is, serositis and pericardial effu-
sion – common to other inflammatory conditions and with
systemic manifestations. Albeit rare, clinicians should re-
member neoplasm and, in particular, PM in those cases in
which pericardial effusion is recurrent and not clearly
explained by other causes.
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Case presentation
Here we report the case of a 45-year-old white woman, a
non-tobacco smoker, affected by PM with systemic auto-
immune manifestations.
First hospitalization
In 2011 she was hospitalized. On examination during ad-
mission, she was afebrile, dyspneic, especially mildly
orthopneic, and tachycardic while her other vital signs
were normal. Her body mass index (BMI) was in the nor-
mal range. No preferential decubitus was noticed and no
peculiar friction rub was heard using the stethoscope.
Laboratory tests
Her blood tests and blood cell count were unremarkable
except for an above normal erythrocyte sedimentation rate
(ESR) and mild anemia of chronic disease (Table 1). She
later underwent a blood sample for antibodies to coxsack-
ievirus, echovirus, cytomegalovirus, and Epstein–Barr
virus, which were all negative, thus ruling out a possible
viral infection.
Instrumental investigations
Several instrumental investigations were performed. An
electrocardiogram showed ST elevation in all leads, sug-
gestive for acute pericarditis. Echocardiography under-
lined the presence of 1 cm-wide pericardial fluids between
the pericardial layers, while no suspected masses were ob-
served. Her atrial and ventricular function as well as myo-
cardial appearance and valves were reported as normal.
An X-ray of her thorax showed a moderate enlargement
of the cardiac shadow. Pericarditis was treated with ibu-
profen and beta-blockers with benefit.
After the first hospitalization, in the following 2 years,
she developed non-erosive polyarthritis, photosensitive
rash, sicca syndrome, and several episodes of pericarditis
with pericardial effusion. A complete laboratory assess-
ment was performed and disclosed antinuclear autoanti-
bodies (ANA 1:320), weak and transient anti-cardiolipin
antibody on two separate occasions (<12 weeks), while
complement proteins C3/C4, extractable nuclear antigens
(ENA), double-stranded (ds) deoxyribonucleic acid (DNA)
and anti-Smith antibodies, were absent or within physio-
logical ranges. Mild anemia and an above normal ESR
with normal C-reactive protein (CRP) were also detected,
while counts of leukocytes with differential, biochemistry
panel, and anti-phospholipid antibodies (anti-cardiolipin,
anti-beta2 glycoprotein I, lupus anticoagulant) were within
normal range (Table 1). The presence of pericardial dis-
ease, polyarthritis, photosensitive skin rash, and positive
ANA test fulfilled the classification criteria for systemic
lupus erythematosus (SLE) [6].
She was treated with prednisone 25 mg/day administered
orally, hydroxychloroquine 400 mg/day, and colchicine 1
mg/day without complete resolution of the pericardial dis-
ease. In the following year, she was frequently hospitalized
for serositis with pericardial effusions, always accompanied
by dyspnea and disease flare with articular symptoms. The
first pericardial episode was successfully treated by increas-
ing her steroids dosage.
An ultrasound (US)-guided pericardiocentesis was per-
formed for diagnostic purposes; cytological and cultural
analysis of pericardial effusion samples resulted negative.
Instead, two more episodes were treated as exacerba-
tions of pericardial disease by increasing corticosteroid
dosage with only partial recovery. Neither symptoms nor
Table 1 Anthropometric measures and laboratory test results during the hospitalizations and clinical evaluations between
2011 and 2014
Findings 2011 Hospitalization Data from other hospital admissions 2014 Hospitalization
Height (cm) 161 – 161
Weight (kg) 56 – 49
Body mass index (BMI, Kg/m2) [18.5–24.99] 21.6 – 18.9
Hemoglobin (g/dL) [12.0–16] 11.1 – 10.6
Serum iron (mcg/mL) [37–147] 31 – 29
Transferrin (g/dL) [0.20–0.37] 0.28 – 0.28
Ferritin (ng/mL) [11–193] 302 – 288
Erythrocyte sedimentation rate (ESR, mm/hour) [0–20] 38 28 44
C-reactive protein (CRP, mg/dL) [0–8] 0.1 0.1 0.1
Anti-nuclear antibodies (ANA) 1/320 Present, titer 1/640, homogenous pattern –
Anti-cardiolipin antibodies (IgG; U/mL) – Positive, 16.2 (2012); positive, 18.7 (2013) –
Extractable nuclear antigens (ENA) – Absent –
Anti-double-stranded deoxyribonucleic acid antibodies – Absent –
Anti-Smith antibodies – Absent –
Square brackets indicate the normal levels of each variable
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signs attributable to constrictive pericarditis were found.
Of note, her ESR levels were consistently above normal,
while her serum CRP concentration was constantly
within the physiological range (Table 1).
Second hospitalization for diagnostic purposes
During her hospitalization in 2014, 3 years after the first
one, her vital signs were still normal, but a moderate
weight loss was noticed (Table 1).
Radiological examinations
Eventually, a thorax computed tomography (CT) scan
was performed and revealed extensive, irregular thick-
ness of pericardial visceral and parietal layers, com-
pletely surrounding her heart, aortic root, pulmonary
arteries, and veins (Fig. 1a, b).
Histological analysis
She underwent pericardiectomy with histological analysis,
revealing neoplastic cell growth with immunophenotypic
profiles positive for calretinin, cytokeratin chorioallantoic
membrane (CAM) 5.2/cytokeratin 7/KL1, and epithelial
membrane antigen (EMA), confirming epithelioid PM. Ac-
cording to the American Cancer Society guidelines, PM
may benefit from surgery, radiotherapy, and chemotherapy
[4]. Unfortunately, the PM was too advanced to be eligible
for surgical removal, and the heart and aortic involvement
ruled out any radiotherapy indication. She was treated with
cisplatin and pemetrexed (Fig. 1c, d) without any clinical
benefit and died 8 months later. Since cases of mesotheli-
oma are subjected to special legislature in Italy and given
the peculiarity of our case, a histological revision was per-
formed by pathologists of another institute, who confirmed
the diagnosis.
Discussion
We retrospectively analyzed this case of PM in a patient
who had not been exposed to asbestos who presented as
having SLE with relapsing pericardial effusions, following
a report to the Lombardy Mesothelioma Registry.
Mesothelioma is a rare cancer of mesothelium, which
commonly develops in people exposed to asbestos. PM only
accounts for 0.7 % of all MM [1]. Its association with con-
nective tissue diseases manifesting with serositis is ex-
tremely rare. In fact, only one case of SLE as a syndrome
related to PM has been described since 1980 [5]. Instead,
the association of PM or peritoneal mesothelioma with in-
flammatory myopathies, seronegative rheumatoid arthritis,
and some atypical vasculitis has been described and re-
ported as paraneoplastic syndromes, although scleroderma-
Fig. 1 Contrast-enhanced computed tomography of the thorax before (a, b) and after (c, d) chemotherapy. a Axial image crossing the left atrium.
b-c Axial images through the ventricles. d Sagittal image through the aortic arch. Before chemotherapy (a, b), both parietal (white arrows) and visceral
(black arrow) layers of the pericardium were very thickened. After chemotherapy (c, d), computed tomography shows progression of the lesions around
ventricles, in cranial sinuses, around the ascending aorta and the pulmonary artery. Legend: A aorta, CV cava vein, L liver, LA left atrium, LV left ventricle,
PL pleural effusion, RV right ventricle, black arrows visceral layer of the pericardium, star neoplastic tissue, white arrows parietal layer of the pericardium
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like and SLE-like syndromes (especially subacute cutaneous
SLE) have also been reported [7–12].
In addition to other clinical manifestations, SLE can
present with serositis, which may delay or complicate
the diagnosis of PM.
In the case described, pericarditis, non-erosive arthritis,
photosensitive rash, and sicca syndrome developed months
before the first episode of pericardial involvement. In
addition, anti-dsDNA and ENA antibodies were negative,
resembling a paraneoplastic syndrome rather than a pri-
mary connective tissue disease. Although neoplasms can be
commonly associated with polymyositis/dermatomyositis
syndromes, the clinical and laboratory picture was not sug-
gestive for these processes: no myalgia, no increased muscle
enzymes, no specific relation with myositis-associated or
myositis-specific auto-autoantibodies, and no rash typical of
dermatomyositis. Moreover, the patient’s CRP levels were
constantly within normal range and the poor response to
corticosteroids should have suggested a cause for the relaps-
ing pericardial effusion other than SLE, as lupus serositis
tends to increase both CRP and ESR levels [13]. Besides, al-
though her arthritis was always accompanied by pericardial
effusions, it did not respond to a moderately high dose of
corticosteroids, which is quite unusual for SLE.
In addition, consideration of the negative pericardial cy-
tology for neoplastic cells and the poor response to cortico-
steroids should have been encouraged oriented radiological
and histological approaches, even if exclusive pericardial
localization of MM is particularly rare, as cytological diag-
nosis of MM is hindered by low sensitivity rates.
Conclusions
In conclusion, clinicians should consider MM and in
particular PM in the differential diagnosis of pericardial
effusion, especially when recurrent and not clearly ex-
plained by other causes. Cytological samples should al-
ways be obtained and, if imaging tools are suggestive for
solid processes, histological confirmation is mandatory.
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